Halter, J; Schüpbach, W M M; Casali, C; Elhasid, R; Fay, K; Hammans, S; Illa, I; Kappeler, L; Krähenbühl, S; Lehmann, T; Mandel, H; Marti, R; Mattle, H; Orchard, K; Savage, D; Sue, C M; Valcarcel, D; Gratwohl, A; Hirano, M (2010). Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone marrow transplantation, 46(3), pp. 330-337. London: Nature Publishing Group 10.1038/bmt.2010.100
Full text not available from this repository. (Request a copy)Allogeneic hematopoietic SCT (HSCT) has been proposed as a treatment for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). HSCT has been performed in nine patients using different protocols with varying success. Based on this preliminary experience, participants of the first consensus conference propose a common approach to allogeneic HSCT in MNGIE. Standardization of the transplant protocol and the clinical and biochemical assessments will allow evaluation of the safety and efficacy of HSCT as well as optimization of therapy for patients with MNGIE.Bone Marrow Transplantation advance online publication, 3 May 2010; doi:10.1038/bmt.2010.100.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Mattle, Heinrich |
ISSN: |
0268-3369 |
Publisher: |
Nature Publishing Group |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:08 |
Last Modified: |
05 Dec 2022 14:00 |
Publisher DOI: |
10.1038/bmt.2010.100 |
PubMed ID: |
20436523 |
Web of Science ID: |
000288164000002 |
URI: |
https://boris.unibe.ch/id/eprint/375 (FactScience: 197876) |
Actions (login required)
 |
Edit item |